Burney Co. Acquires 13,259 Shares of Pfizer Inc. (NYSE:PFE)

Burney Co. increased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 9.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 156,990 shares of the biopharmaceutical company's stock after buying an additional 13,259 shares during the quarter. Burney Co.'s holdings in Pfizer were worth $3,978,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Brooktree Capital Management grew its holdings in shares of Pfizer by 2.4% during the first quarter. Brooktree Capital Management now owns 118,171 shares of the biopharmaceutical company's stock valued at $2,994,000 after buying an additional 2,788 shares during the last quarter. Summit Wealth Partners LLC boosted its position in shares of Pfizer by 6.0% during the first quarter. Summit Wealth Partners LLC now owns 26,644 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 1,507 shares during the last quarter. Granite Group Advisors LLC boosted its position in shares of Pfizer by 37.9% during the first quarter. Granite Group Advisors LLC now owns 47,033 shares of the biopharmaceutical company's stock valued at $1,192,000 after buying an additional 12,919 shares during the last quarter. Old Port Advisors boosted its position in shares of Pfizer by 8.8% during the first quarter. Old Port Advisors now owns 89,293 shares of the biopharmaceutical company's stock valued at $2,263,000 after buying an additional 7,218 shares during the last quarter. Finally, Accredited Investors Inc. boosted its holdings in Pfizer by 3.2% during the 1st quarter. Accredited Investors Inc. now owns 19,698 shares of the biopharmaceutical company's stock worth $499,000 after acquiring an additional 605 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 2.2%

Shares of NYSE PFE traded down $0.57 during midday trading on Friday, reaching $24.79. The company had a trading volume of 35,628,980 shares, compared to its average volume of 38,205,096. The firm's fifty day moving average price is $24.30 and its 200-day moving average price is $24.66. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock has a market cap of $140.91 billion, a PE ratio of 17.96, a price-to-earnings-growth ratio of 0.90 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.82 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.94%. Pfizer's dividend payout ratio (DPR) is 124.64%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Redburn Atlantic cut their price objective on Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 30th. The Goldman Sachs Group upped their price objective on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Leerink Partners cut their price target on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. Finally, BMO Capital Markets dropped their price objective on shares of Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer has an average rating of "Hold" and an average target price of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.